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An Interview 
With Dr. Lewis Thomas 
Ttie Road 
CO 
Research 
n long the tile corridor of the sixth floor of Memorial Sloan-Kettering Cancer Center in New York City stand cylinders of compressed 
gas, portable trays on wheels, metal stands holding 
plastic jugs of colorless liquids, and cabinets filled 
with beakers, glasses, and boxes of chemicals. One 
passes labs with glass tubing and glowing Bunsen 
burners, refrigerated labs behind metal doors, and 
white -coated men and women. At the end of the hall 
is the office of Dr. Lewis Thomas, chancellor of the 
institute as well as the author of such renowned 
books as The Lives of a Cell, The Medusa and the 
Snail, and, most recently, The Youngest Science, Notes 
of a Medicine-Watcher. 
Dr. Thomas is a soft-spoken scientist whose 
outward calm belies his invigorating mind. As he 
discusses issues facing the scientific and business 
communities, he chooses to focus on what he calls the 
"intellectual connections" between the two fields, 
particularly the shared concerns about basic and 
applied research. 
His thoughts come slowly, softly. His fingers move 
gently, cupping a cigarette, twirling tortoise shell 
glasses, cradling his jaw as he speaks. The following 
is an edited version of a recent conversation. 
You have said that you are not sure that the 
term "high technology" could be applied to the 
biomedical field. Would you care to explain? 
What I meant is that I don't regard machinery, such 
as a CAT scanner or the artificial heart, as represent-
ing high technology. I think today's version of high 
technology in the biomedical field is the working out 
of techniques for manipulating DNA in vivo. Recom-
binant DNA is an advance that I would regard as the 
greatest thing that has ever happened in biological 
science. It is now possible for cell biologists and 
immunologists and molecular geneticists to get 
answers that were inconceivable just a few years ago. 
I think that when historians one day write about the 
biological revolution, they'll date it in the past decade. 
The significance of recombinant DNA technology is 
that we can now begin to look at events not just 
inside the cell but inside the intricate machinery of 
these cells, and this means to me that we ought to be 
able to explore disease mechanisms in a way we've 
never been able to do before. This is why I'm so 
optimistic about our being able to do something 
decisive with the problem of cancer in some sort of 
real time. The work is moving very fast, and the 
investigators who are doing this work are extremely 
enthusiastic, highly competent, and pretty sure that 
before long they're going to understand what goes on 
at a deep level in cancer. And when that happens, it is 
likely that we will be able to devise either pharmaco-
logical or immunological approaches that we would 
not have been able to come up with otherwise. 
So the great need in medicine is for more basic 
biomedical research, and I would like to talk about 
something fascinating that is happening today in 
this field. 
What do you see taking place? 
Well, there are new connections being made between 
industrial science and academic science. It used to be 
that industrial science—or applied science—was 
targeted toward a product, while what -went on in the 
university world was largely basic science that was 
aimed at acquiring an understanding of the mecha-
nisms in nature. And there was no connection 
between those two communities. A few decades ago, 
this changed in the physical sciences, as institutions 
like MIT and Cal-Tech began working with the 
industrial world, and some major corporations began 
investing in basic science in the universities. But this 
didn't happen in biomedical science until recently. 
Why did it happen in the other fields and not in 
medicine? 
I think it became quite clear after World War II that 
there were problems of deep concern to the corporate 
world which could be solved only by making use of 
the basic science information being generated in the 
university laboratories. I don't know why it didn't 
happen simultaneously in biomedical science. Perhaps 
it was because the academic people felt that any 
connection to industry and the marketplace would 
somehow contaminate them and lead them away 
from their primary objective of understanding the 
mechanisms of nature. I think, though, that the main 
problem was that the two communities simply 
existed apart from each other. They didn't go to the 
same meetings, didn't belong to the same societies. 
And the change has come about because there has 
been a revolution in science in the academic world. It 
became clear to everybody that there would be 
practical applications of this new science, and the 
corporate world was interested. 
But it should also be said that the university world 
no longer has a feeling of apprehension about intel-
lectual contact with the corporate world. I could cite 
the Hoechst contract with Massachusetts General 
Hospital that provides a large sum of money over 20 
years to support pure basic research in molecular 
genetics. There is no requirement that the Harvard 
scientists in the Mass. General laboratories choose a 
line of research that would be of special interest to a 
pharmaceutical house, much less any obligation to 
produce a product. The only quid pro quo I'm aware 
of is that the corporation gets the first look at the 
basic science as it comes out, and if it looks interesting 
they have the first option to turn it into a product. 
There are similar arrangements between Du Pont 
and the Harvard Medical School, as well as Johnson 
and Johnson and the Scripps Clinic and Research 
Foundation in California—plus a good many others 
now on-line. Now, I can't imagine that such a 
partnership with industry could ever cover more than 
10 percent of a lab's research costs, but what it does 
is provide long-term support that the government 
doesn't provide. Government support comes in two-
year awards from the National Institutes of Health 
(NIH), and the young investigators feel these days 
that they are in a very unstable environment if they 
depend entirely on NIH grants. In fact, there has been 
a recent tendency to take on research problems that 
look absolutely sound and which promise results 
within 12 to 18 months. So the new arrangements 
with industry mean that the investigators don't need 
to be apprehensive about their salaries and can 
undertake longer-term approaches to research. And 
the ability to gamble in the laboratory is what has 
made American science the best science on earth. 
So you are comfortable with these new 
financial resources. 
Yes, but I'm worried, too. I'm worried that sooner or 
later we may start neglecting some fields of science. I 
sense a belief in Washington that there is not enough 
money to do basic research across the board in 
biology, in physics, in chemistry, and so we should 
support these fields which look as though they have 
some promise for the 1990s. I see a great danger in 
committees sitting down and trying to figure out 
what's going to be important 10 or 20 years from 
now. It would never have crossed anyone's mind in 
the 1960s what we are able to do today in manipu-
lating genes, of inserting genes from one kind of cell 
into a different cell. What we had was a lot of 
research in molecular biology being done just because 
it was fascinating to young scientists. 
Science, you're saying, is built on long-range 
thinking. 
Not in research itself, not at all. Basic research is done 
by people who want quick answers to engrossing 
questions. But they are also aware of two other 
things. First, your original guess is probably going to 
turn out to be wrong. You can write a 100-page 
application to NIH saying exactly what you're going 
to do the next two years; but if you're a good investi-
gator, you'll put that aside as soon as you start, 
because you're going to notice things you hadn't 
expected to see and soon find yourself in a different 
world. The second lesson is that you never finish. As 
soon as you reach what you think is the final answer 
to a problem, it stops becoming a final answer and 
becomes an array of new questions. So in that sense 
you could say it is long-range thinking. 
Who has changed, then, the basic scientist or 
the applied scientist, as they now work together? 
Well, it comes back to both sides realizing that you're 
not going to get any applied science solutions falling 
into your lap without a lot of basic inquiry happening 
beforehand. I think we in the academic world have 
tended to look down our noses at industrial science in 
the past as not pure science but just a way of 
making money. And now there are some very 
amiable and exciting relationships beginning to start 
up between these two scientific worlds; and, if 
handled carefully, this could be a wonderful thing for 
our country. It could put us in a better competitive 
position with both Europe and Japan, where there's a 
closer connection between applied and basic science. 
What do you mean, handled carefully? 
There is anxiety in the university world over the issue 
of confidentiality and secrecy—that the needs for 
patents and licensing will delay information coming 
out of the basic research laboratory. But I think that if 
the information is patentable, it will not take all that 
time to get the machinery cranked up. So I don't see 
a restraint on publication. What I am worried about 
is that there may be less free gossiping in the halls of 
university science. When the bright investigators I 
know run into something interesting in their lab, they 
can't wait until lunch time to tell everyone else. And 
this communication system based on phone calls, 
corridor gossip, and international meetings is very 
effective. So I worry that investigators may think that 
if they tell what is going on in their laboratory, 
someone else may pick it up, and they'll lose their 
priority on it. It's not something to worry about now, 
but we should be apprehensive about it in the future. 
Do you think the public understands how 
basic science works? 
No. In fact, I think the public worries about what 
scientists may be doing to the world. They associate 
technology—such as for thermonuclear weapons— 
with science much more closely than they should. 
Technology is one thing, and science is another. 
Society, through its elected officials, certainly ought to 
choose between what technology it wants and what it 
doesn't want; but, as I said, you can't make choices in 
basic science. There aren't any questions that should 
be disallowed, because you can't predict how the 
inquiry is going to turn out. 
Even when there is apprehension, such as that 
concerning genetic engineering? 
Well, we've had a long run now in molecular genetics 
—almost 10 years—since the scientists themselves first 
cited the possible dangers of gene transfers. So there 
was a moratorium for a while, and a lot of guidelines 
were established by the NIH which are still in effect; 
and there's been no evidence of any accident, not even 
of any risk. Quite clearly, nothing has gone wrong. 
There's a general agreement now within the scientific 
community that such research applications as inter-
feron and the cloning of genetic information essen-
tially carry no risk at all. But there is still a feeling in 
the public mind that fooling around with the genome 
is something we ought not to be doing. 
The genome? 
That's jargon for the entire genetic machinery in the 
nucleus of the cells. The interest, you see, lies in 
replacing DNA that may be congenitally lacking in 
cells; for when it is, some people don't have the right 
enzymes that are essential for life. And while it can't 
be done now, replacing that DNA information 
sometime in the future could save the lives of children 
who -would otherwise die. But I don't think this so-
called genetic engineering will ever be applied to the 
germ plasm itself. 
Out of choice or the lack of technology? 
Both. It's a complicated ethical question, really, and I 
don't see much interest in the scientific community to 
go ahead with this kind of work. I can't imagine 
anybody in science ever -wanting to become involved 
in the cloning of a human being, for example, even if 
one day it could be done. Besides, it would require 
the whole GNP just to support the research, because 
you'd have to clone parents, grandparents, aunts, 
uncles, cousins—the entire environment—and that's a 
science fiction invention. I think that what is needed 
is a better case made by the scientific community for 
what is going on in basic research. The main thing 
that is happening is that we're beginning to under-
stand how life works. When people look back at the 
twentieth century, the most important discovery of 
science may be that we learned how little we know 
about our origins, about how our minds -work, and 
how we live together. In preceding centuries -we 
thought we knew everything; in this century, we have 
discovered through science how ignorant we are. 
It sounds like there is a communications gap 
here. Is it not difficult for science to 
communicate its potential to the public? 
Yes, and one of my preoccupations these days is to 
help the general literate public understand what is 
going on in science. So I am helping to develop a 
series of books by -working scientists. They will be on 
everything from galactic cosmology to molecular 
genetics. What happened, for example, during that 
major portion of the earth's existence up to a billion 
years ago when there was nothing but bacteria and 
perhaps their viruses? Biological habits originated 
then that have persisted. Another subject is clinical 
science. How do you actually do research with human 
patients? What are the objectives? What ethical 
problems exist? 
Are there going to be certain scientific 
discoveries down the road that confront us with 
ethical decisions? 
We scientists may have to confront some ethical 
choices. For example, there's something about cloning 
individuals that I myself find a plain violation of the 
human spirit—it would be wrong. I would take a 
stand that it should be forbidden. But even in that case 
it would not be science itself that would raise the 
ethical question; it would be the application of the 
science that would do so. Let's take a more realistic 
possibility—that we -will be able to transplant human 
organs with ease. That also is technology, and 
-whether or not to spend money on basic science to 
make that possible should be a public decision. It 
should not be a decision made by doctors or biomed-
ical scientists. It should be made by Congress and 
the people. 
Would you sum up your thoughts about the 
basic and applied sciences, and the role of 
research in our society? 
We are an industrial society, and the whole -world is 
becoming one as -well. If we are going to be successful 
in developing the technologies that we need in order 
to survive as a species, we need to be totally depen-
dent on basic research. The topmost priority in the 
United States of America ought to be the fostering of 
a fundamental inquiry into nature, without imposing 
targets, without trying to choose between fields. 
Research in marine biology should be just as impor-
tant as research on human DNA, and that extends to 
laser communications, to artificial intelligence, to all 
physics, chemistry, and the biological sciences. I think 
we can afford it. I know we're good at it, and we 
ought to be enlisting our brightest young people to do 
it. I think the future depends on it. & 
